Scientists discover the body’s hidden “off switch” for inflammation
A human study in Nature Communications found fat-derived epoxy-oxylipins drive monocyte fate to resolve inflammation; boosting these molecules with a drug reduced pain and lowered pro-inflammatory cells, suggesting new targets for arthritis, heart disease, and other chronic inflammation therapies.
Why it mattersUniversity College London’s epoxy-oxylipins finding directs drug development to prioritize inflammation-resolving therapies for arthritis.